Skip to content

A potential first-in-class pruritus treatment

Cara Therapeutics is developing a peripherally acting kappa opioid receptor (KOR) agonist called difelikefalin.

Difelikefalin is currently being studied in ongoing clinical trials for multiple indications.

References: 1. Spencer R, Lewis M, Stauffer J, Mathur M, Menzaghi F. Anti-pruritic effect of the long-acting peripheral kappa opioid receptor agonist CR845: a novel approach for the treatment of uremic pruritus in hemodialysis patients. Presented at Kidney Week 2016; November 15-20, 2016; Chicago, IL. 2. Spencer R, Gardell L, Desai R, Menzaghi F. Anti-inflammatory effects of the peripheral kappa opioid receptor agonist CR845: a novel approach for the treatment of inflammatory disease. Presented at IASP 2010; September 3, 2010; Montreal, Canada.